StreetInsider.com News Articles

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Faust Elizabeth

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640970.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Faust Elizabeth

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640970.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: AGUIAR ERIC

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640977.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: AGUIAR ERIC

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640977.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Ray Sumita

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640982.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Ray Sumita

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640982.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Averill Julianne

Fri, 12 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260612/26640960.html

Form 4 Biomea Fusion, Inc. For: Jun 10 Filed by: Averill Julianne

Fri, 12 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260612/26640960.html

Form 8-K Biomea Fusion, Inc. For: Jun 10

Thu, 11 Jun 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260611/26632553.html

Form 8-K Biomea Fusion, Inc. For: Jun 10

Thu, 11 Jun 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260611/26632553.html

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 S

Fri, 05 Jun 2026 19:32:00 -0400

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 S

Fri, 05 Jun 2026 19:32:00 -0400

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor

Biomea Fusion partners with University of Leicester for obesity study

Wed, 03 Jun 2026 08:03:50 -0400

Biomea Fusion Inc. (NASDAQ: BMEA) announced a research collaboration with the University of Leicester to evaluate its investigational drug icovamenib in combination with semaglutide for obesity treatment.
The study will be conducted as part of the University of Leicester's ongoing OPAL platform trial, led by Professors Melanie Davies and Thomas Yates at the Leicester Diabetes Centre. The randomized, double-blind trial will assess whether adding icovamenib to GLP-1 therapy enhances weight loss effects compared to semaglutide alone.
The experimental arm will evaluate icovamenib at 100 mg daily for 12 weeks combined with low-dose semaglutide for 24 weeks versus semaglutide alone for 24 weeks

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Wed, 03 Jun 2026 08:00:00 -0400

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes
Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health

SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Wed, 03 Jun 2026 08:00:00 -0400

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes
Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health

SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing

Biomea Fusion to Participate at Upcoming Investor Conferences

Tue, 12 May 2026 16:05:00 -0400

SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences:

H.C. Wainwright 4th Annual BioConnect Investor Conference: Biomea will participate in a fireside chat from 3:00–3:30 PM ET and in one-on-one meetings on May 19, 2026, in New York, NY.

2026 Jefferies Global Healthcare Conference: Biomea will participate in a fireside chat from 8:10–8:40 AM ET and in one-on-one meetings on June 4, 2026, in New York, NY.

Biomea Fusion to Participate at Upcoming Investor Conferences

Tue, 12 May 2026 16:05:00 -0400

SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences:

H.C. Wainwright 4th Annual BioConnect Investor Conference: Biomea will participate in a fireside chat from 3:00–3:30 PM ET and in one-on-one meetings on May 19, 2026, in New York, NY.

2026 Jefferies Global Healthcare Conference: Biomea will participate in a fireside chat from 8:10–8:40 AM ET and in one-on-one meetings on June 4, 2026, in New York, NY.

Biomea Fusion, Inc. (BMEA) Tops Q1 EPS by 6c

Mon, 11 May 2026 17:39:15 -0400

Biomea Fusion, Inc. (NASDAQ: BMEA) reported Q1 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23).
For earnings history and earnings-related data on Biomea Fusion, Inc. (BMEA) click here.

Form 10-Q Biomea Fusion, Inc. For: Mar 31

Mon, 11 May 2026 17:02:00 -0400
si-local-file:///var/storage/secattach/20260511/26470380.html

Form 10-Q Biomea Fusion, Inc. For: Mar 31

Mon, 11 May 2026 17:02:00 -0400
si-local-file:///var/storage/secattach/20260511/26470380.html

Form 8-K Biomea Fusion, Inc. For: May 11

Mon, 11 May 2026 16:58:00 -0400
si-local-file:///var/storage/secattach/20260511/26470280.html

Form 8-K Biomea Fusion, Inc. For: May 11

Mon, 11 May 2026 16:58:00 -0400
si-local-file:///var/storage/secattach/20260511/26470280.html

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Mon, 11 May 2026 16:54:00 -0400

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date
Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of action
First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026
The Phase I GLP-131 (BMF-650) obesity clinical trial is on track; initial 28-day weight

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Mon, 11 May 2026 16:54:00 -0400

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date
Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of action
First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026
The Phase I GLP-131 (BMF-650) obesity clinical trial is on track; initial 28-day weight

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Mon, 11 May 2026 16:54:00 -0400

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date
Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of action
First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026
The Phase I GLP-131 (BMF-650) obesity clinical trial is on track; initial 28-day weight